EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis

Zuzana Outla iD, Gizem Oyman-Eyrilmez, Katerina Korelova, Magdalena Prechova, Lukas Frick, Lenka Sarnova, Piyush Bisht, Petra Novotna, Jan Kosla, Patricia Bortel, Yasmin Borutzki, Andrea Bileck und 19 weitere

eLife · 07.03.2025 · 13

DOI: 10.7554/elife.102205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 07.03.2025. Verfasst von Zuzana Outla und 30 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic. Hauptthemen laut MEDLINE: Plectin, Carcinoma, Hepatocellular, Liver Neoplasms, Cytoskeleton. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grantová Agentura České Republiky, Ministerstvo Školství, Mládeže a Tělovýchovy, Next Generation EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most common primary malignancy of the liver, hepatocellular carcinoma (HCC), is a heterogeneous tumor entity with high metastatic potential and complex pathophysiology. Increasing evidence suggests that tissue mechanics plays a critical role in tumor onset and progression. Here, we show that plectin, a major cytoskeletal crosslinker protein, plays a crucial role in mechanical homeostasis and mechanosensitive oncogenic signaling that drives hepatocarcinogenesis. Our expression analyses revealed elevated plectin levels in liver tumors, which correlated with poor prognosis for HCC patients. Using autochthonous and orthotopic mouse models we demonstrated that genetic and pharmacological inactivation of plectin potently suppressed the initiation and growth of HCC. Moreover, plectin targeting potently inhibited the invasion potential of human HCC cells and reduced their metastatic outgrowth in the lung. Proteomic and phosphoproteomic profiling linked plectin-dependent disruption of cytoskeletal networks to attenuation of oncogenic FAK, MAPK/Erk, and PI3K/Akt signatures. Importantly, by combining cell line-based and murine HCC models, we show that plectin inhibitor plecstatin-1 (PST) is well-tolerated and potently inhibits HCC progression. In conclusion, our study demonstrates that plectin-controlled cytoarchitecture is a key determinant of HCC development and suggests that pharmacologically induced disruption of mechanical homeostasis may represent a new therapeutic strategy for HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlectinCarcinoma, HepatocellularLiver NeoplasmsCytoskeletonAnimalsHumansMiceCell Line, TumorNeoplasm MetastasisSignal TransductionCell ProliferationDisease Models, Animal

Stichwörter der Autor:innen

cancer biologycell biologycytoskeletal crosstalkhepatocellular carcinomametastasismouseplecstatinplectintherapeutic strategy

Substanzen

Plectin

Autor:innen und Institutionen

  • Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
  • Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
  • Division of Chronic Inflammation and Cancer, German Cancer Research Center, Im Neuenheimer Feld, Heidelberg, Germany.
  • Department of Analytical Chemistry, University of Vienna, Vienna, Austria.
  • Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria.
  • Joint Metabolome Facility, Medical University of Vienna and University of Vienna, Heidelberg, Germany.

ORCID-Profile: Zuzana Outla, Daniel Rösel, Gerhard Wiche, Martin Gregor

Förderung

  • Grantová Agentura České Republiky
  • Ministerstvo Školství, Mládeže a Tělovýchovy
  • Next Generation EU
  • ERDF
  • Ministry of Health of the Czech Republic

Zitieren

APA

Outla, Z., Oyman-Eyrilmez, G., Korelova, K., Prechova, M., Frick, L., Sarnova, L., Bisht, P., Novotna, P., Kosla, J., Bortel, P., Borutzki, Y., Bileck, A., Gerner, C., Rahbari, M., Rahbari, N., Birgin, E., Kvasnicova, B., Galisova, A., Sulkova, K., …, & Gregor, M. (2025). Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis. eLife, 13. https://doi.org/10.7554/elife.102205

Vancouver

Outla Z, Oyman-Eyrilmez G, Korelova K, Prechova M, Frick L, Sarnova L, et al. Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis. eLife. 2025;13. doi:10.7554/elife.102205

BibTeX
@article{Outla2025,
  author = {Outla, Zuzana and Oyman-Eyrilmez, Gizem and Korelova, Katerina and Prechova, Magdalena and Frick, Lukas and Sarnova, Lenka and Bisht, Piyush and Novotna, Petra and Kosla, Jan and Bortel, Patricia and Borutzki, Yasmin and Bileck, Andrea and Gerner, Christopher and Rahbari, Mohammad and Rahbari, Nuh and Birgin, Emrullah and Kvasnicova, Bibiana and Galisova, Andrea and Sulkova, Katerina and Bauer, Andreas and Jobe, Njainday and Tolde, Ondrej and Sticova, Eva and Rösel, Daniel and O'Connor, Tracy and Otahal, Martin and Jirak, Daniel and Heikenwälder, Mathias and Wiche, Gerhard and Meier-Menches, Samuel M and Gregor, Martin},
  title = {Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis},
  journal = {eLife},
  year = {2025},
  volume = {13},
  doi = {10.7554/elife.102205}
}
Kostenlos starten →